Allogeneic peripheral blood stem cell transplantation in 23 adult patients with hematologic malignancies: A single-center experience

Katsuto Takenaka, Katsuji Shinagawa, Kazutaka Sunami, Nobuharu Fujii, Yasushi Hiramatsu, Yoshinobu Maeda, Yuichiro Nawa, Yoshio Katayama, Takanori Teshima, Fumihiko Ishimaru, Katsuyuki Kiura, Kazuma Ikeda, Mine Harada

Research output: Contribution to journalArticle

Abstract

We describe a single-center experience of 23 consecutive patients (median age, 35 years) with hematologic malignancies who received allogeneic peripheral blood stem cell transplants (alloPBSCTs) from HLA-identical siblings. Ten patients had standard-risk disease and 13 had high-risk disease. Twenty-one patients received alloPBSCT as a primary transplant, and the remaining 2, with high-risk disease, as a second transplant after posttransplantation relapse. All donors received daily subcutaneous injections of granulocyte colony-stimulating factor at a dose of 10 μg/kg, and peripheral blood stem cells were collected by 1 to 3 aphereses. Median numbers of CD34+ and CD3+ cells infused were 5.8 × 106/kg (range, 1.3-19.7 × 106/kg) and 4.9 × 103/kg (range, 1.9-8.6 × 103/kg), respectively. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A (CyA) and methotrexate (18 patients) or CyA and methylprednisolone (5 patients). Rapid hematologic engraftment was observed in 20 of the 23 patients. Median days to absolute neutrophil counts >0.5 × 109/L and platelet counts >20 × 109/L were 12 (range, 9-18 days) and 14 (range, 10-128 days), respectively. Acute GVHD of grade 2-4 was observed in 6 of 20 evaluable patients (30%) and extensive chronic GVHD in 8 of 15 evaluable patients (53%).Ten of the 23 patients (44%) were surviving in continuous complete remission 191 to 1492 days (median, 643 days) posttransplantation. Treatment-related death within 100 days posttransplantation was observed in 6 of the 23 patients (26%). Six of the 23 patients (26%) developed relapse at a median 81 days (range, 38-160 days) posttransplantation. Further study is needed to assess the precise benefits of alloPBSCT compared with allogeneic bone marrow transplantation.

Original languageEnglish
Pages (from-to)362-370
Number of pages9
JournalInternational Journal of Hematology
Volume72
Issue number3
Publication statusPublished - Dec 1 2000

Fingerprint

Peripheral Blood Stem Cell Transplantation
Hematologic Neoplasms
Graft vs Host Disease
Transplants
Cyclosporine
Recurrence
Blood Component Removal
Homologous Transplantation
Methylprednisolone
Granulocyte Colony-Stimulating Factor
Subcutaneous Injections
Bone Marrow Transplantation
Platelet Count
Methotrexate
Siblings
Neutrophils
Tissue Donors

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Takenaka, K., Shinagawa, K., Sunami, K., Fujii, N., Hiramatsu, Y., Maeda, Y., ... Harada, M. (2000). Allogeneic peripheral blood stem cell transplantation in 23 adult patients with hematologic malignancies: A single-center experience. International Journal of Hematology, 72(3), 362-370.

Allogeneic peripheral blood stem cell transplantation in 23 adult patients with hematologic malignancies : A single-center experience. / Takenaka, Katsuto; Shinagawa, Katsuji; Sunami, Kazutaka; Fujii, Nobuharu; Hiramatsu, Yasushi; Maeda, Yoshinobu; Nawa, Yuichiro; Katayama, Yoshio; Teshima, Takanori; Ishimaru, Fumihiko; Kiura, Katsuyuki; Ikeda, Kazuma; Harada, Mine.

In: International Journal of Hematology, Vol. 72, No. 3, 01.12.2000, p. 362-370.

Research output: Contribution to journalArticle

Takenaka, K, Shinagawa, K, Sunami, K, Fujii, N, Hiramatsu, Y, Maeda, Y, Nawa, Y, Katayama, Y, Teshima, T, Ishimaru, F, Kiura, K, Ikeda, K & Harada, M 2000, 'Allogeneic peripheral blood stem cell transplantation in 23 adult patients with hematologic malignancies: A single-center experience', International Journal of Hematology, vol. 72, no. 3, pp. 362-370.
Takenaka, Katsuto ; Shinagawa, Katsuji ; Sunami, Kazutaka ; Fujii, Nobuharu ; Hiramatsu, Yasushi ; Maeda, Yoshinobu ; Nawa, Yuichiro ; Katayama, Yoshio ; Teshima, Takanori ; Ishimaru, Fumihiko ; Kiura, Katsuyuki ; Ikeda, Kazuma ; Harada, Mine. / Allogeneic peripheral blood stem cell transplantation in 23 adult patients with hematologic malignancies : A single-center experience. In: International Journal of Hematology. 2000 ; Vol. 72, No. 3. pp. 362-370.
@article{4a29eb77369143daa92203043ac24e11,
title = "Allogeneic peripheral blood stem cell transplantation in 23 adult patients with hematologic malignancies: A single-center experience",
abstract = "We describe a single-center experience of 23 consecutive patients (median age, 35 years) with hematologic malignancies who received allogeneic peripheral blood stem cell transplants (alloPBSCTs) from HLA-identical siblings. Ten patients had standard-risk disease and 13 had high-risk disease. Twenty-one patients received alloPBSCT as a primary transplant, and the remaining 2, with high-risk disease, as a second transplant after posttransplantation relapse. All donors received daily subcutaneous injections of granulocyte colony-stimulating factor at a dose of 10 μg/kg, and peripheral blood stem cells were collected by 1 to 3 aphereses. Median numbers of CD34+ and CD3+ cells infused were 5.8 × 106/kg (range, 1.3-19.7 × 106/kg) and 4.9 × 103/kg (range, 1.9-8.6 × 103/kg), respectively. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A (CyA) and methotrexate (18 patients) or CyA and methylprednisolone (5 patients). Rapid hematologic engraftment was observed in 20 of the 23 patients. Median days to absolute neutrophil counts >0.5 × 109/L and platelet counts >20 × 109/L were 12 (range, 9-18 days) and 14 (range, 10-128 days), respectively. Acute GVHD of grade 2-4 was observed in 6 of 20 evaluable patients (30{\%}) and extensive chronic GVHD in 8 of 15 evaluable patients (53{\%}).Ten of the 23 patients (44{\%}) were surviving in continuous complete remission 191 to 1492 days (median, 643 days) posttransplantation. Treatment-related death within 100 days posttransplantation was observed in 6 of the 23 patients (26{\%}). Six of the 23 patients (26{\%}) developed relapse at a median 81 days (range, 38-160 days) posttransplantation. Further study is needed to assess the precise benefits of alloPBSCT compared with allogeneic bone marrow transplantation.",
author = "Katsuto Takenaka and Katsuji Shinagawa and Kazutaka Sunami and Nobuharu Fujii and Yasushi Hiramatsu and Yoshinobu Maeda and Yuichiro Nawa and Yoshio Katayama and Takanori Teshima and Fumihiko Ishimaru and Katsuyuki Kiura and Kazuma Ikeda and Mine Harada",
year = "2000",
month = "12",
day = "1",
language = "English",
volume = "72",
pages = "362--370",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Allogeneic peripheral blood stem cell transplantation in 23 adult patients with hematologic malignancies

T2 - A single-center experience

AU - Takenaka, Katsuto

AU - Shinagawa, Katsuji

AU - Sunami, Kazutaka

AU - Fujii, Nobuharu

AU - Hiramatsu, Yasushi

AU - Maeda, Yoshinobu

AU - Nawa, Yuichiro

AU - Katayama, Yoshio

AU - Teshima, Takanori

AU - Ishimaru, Fumihiko

AU - Kiura, Katsuyuki

AU - Ikeda, Kazuma

AU - Harada, Mine

PY - 2000/12/1

Y1 - 2000/12/1

N2 - We describe a single-center experience of 23 consecutive patients (median age, 35 years) with hematologic malignancies who received allogeneic peripheral blood stem cell transplants (alloPBSCTs) from HLA-identical siblings. Ten patients had standard-risk disease and 13 had high-risk disease. Twenty-one patients received alloPBSCT as a primary transplant, and the remaining 2, with high-risk disease, as a second transplant after posttransplantation relapse. All donors received daily subcutaneous injections of granulocyte colony-stimulating factor at a dose of 10 μg/kg, and peripheral blood stem cells were collected by 1 to 3 aphereses. Median numbers of CD34+ and CD3+ cells infused were 5.8 × 106/kg (range, 1.3-19.7 × 106/kg) and 4.9 × 103/kg (range, 1.9-8.6 × 103/kg), respectively. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A (CyA) and methotrexate (18 patients) or CyA and methylprednisolone (5 patients). Rapid hematologic engraftment was observed in 20 of the 23 patients. Median days to absolute neutrophil counts >0.5 × 109/L and platelet counts >20 × 109/L were 12 (range, 9-18 days) and 14 (range, 10-128 days), respectively. Acute GVHD of grade 2-4 was observed in 6 of 20 evaluable patients (30%) and extensive chronic GVHD in 8 of 15 evaluable patients (53%).Ten of the 23 patients (44%) were surviving in continuous complete remission 191 to 1492 days (median, 643 days) posttransplantation. Treatment-related death within 100 days posttransplantation was observed in 6 of the 23 patients (26%). Six of the 23 patients (26%) developed relapse at a median 81 days (range, 38-160 days) posttransplantation. Further study is needed to assess the precise benefits of alloPBSCT compared with allogeneic bone marrow transplantation.

AB - We describe a single-center experience of 23 consecutive patients (median age, 35 years) with hematologic malignancies who received allogeneic peripheral blood stem cell transplants (alloPBSCTs) from HLA-identical siblings. Ten patients had standard-risk disease and 13 had high-risk disease. Twenty-one patients received alloPBSCT as a primary transplant, and the remaining 2, with high-risk disease, as a second transplant after posttransplantation relapse. All donors received daily subcutaneous injections of granulocyte colony-stimulating factor at a dose of 10 μg/kg, and peripheral blood stem cells were collected by 1 to 3 aphereses. Median numbers of CD34+ and CD3+ cells infused were 5.8 × 106/kg (range, 1.3-19.7 × 106/kg) and 4.9 × 103/kg (range, 1.9-8.6 × 103/kg), respectively. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A (CyA) and methotrexate (18 patients) or CyA and methylprednisolone (5 patients). Rapid hematologic engraftment was observed in 20 of the 23 patients. Median days to absolute neutrophil counts >0.5 × 109/L and platelet counts >20 × 109/L were 12 (range, 9-18 days) and 14 (range, 10-128 days), respectively. Acute GVHD of grade 2-4 was observed in 6 of 20 evaluable patients (30%) and extensive chronic GVHD in 8 of 15 evaluable patients (53%).Ten of the 23 patients (44%) were surviving in continuous complete remission 191 to 1492 days (median, 643 days) posttransplantation. Treatment-related death within 100 days posttransplantation was observed in 6 of the 23 patients (26%). Six of the 23 patients (26%) developed relapse at a median 81 days (range, 38-160 days) posttransplantation. Further study is needed to assess the precise benefits of alloPBSCT compared with allogeneic bone marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0034304872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034304872&partnerID=8YFLogxK

M3 - Article

C2 - 11185996

AN - SCOPUS:0034304872

VL - 72

SP - 362

EP - 370

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -